Literature DB >> 26555038

Bacterial prostatitis.

Bradley C Gill1, Daniel A Shoskes.   

Abstract

PURPOSE OF REVIEW: The review provides the infectious disease community with a urologic perspective on bacterial prostatitis. Specifically, the article briefly reviews the categorization of prostatitis by type and provides a distillation of new findings published on bacterial prostatitis over the past year. It also highlights key points from the established literature. RECENT
FINDINGS: Cross-sectional prostate imaging is becoming more common and may lead to more incidental diagnoses of acute bacterial prostatitis. As drug resistance remains problematic in this condition, the reemergence of older antibiotics such as fosfomycin, has proven beneficial. With regard to chronic bacterial prostatitis, no clear clinical risk factors emerged in a large epidemiological study. However, bacterial biofilm formation has been associated with more severe cases. Surgery has a limited role in bacterial prostatitis and should be reserved for draining of a prostatic abscess or the removal of infected prostatic stones.
SUMMARY: Prostatitis remains a common and bothersome clinical condition. Antibiotic therapy remains the basis of treatment for both acute and chronic bacterial prostatitis. Further research into improving prostatitis treatment is indicated.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26555038     DOI: 10.1097/QCO.0000000000000222

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  10 in total

1.  Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Bo Bo W Maung; Farehin Khan; Ieva Alisauskaite; Melanie Olesky; Joseph Newman; Abdul Mutlib; Xiaoyun Niu; Michael Satlin; Ravi S Singh; Harmut Derendorf; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

Review 2.  Applications of Vertebrate Models in Studying Prostatitis and Inflammation-Associated Prostatic Diseases.

Authors:  Joosje Bleeker; Zhu A Wang
Journal:  Front Mol Biosci       Date:  2022-07-05

3.  Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales.

Authors:  Kévin Bouiller; Souheil Zayet; Paul-Emile Lalloz; Anaïs Potron; Vincent Gendrin; Catherine Chirouze; Timothée Klopfenstein
Journal:  Antibiotics (Basel)       Date:  2022-02-03

4.  Immunological Tolerance, Pregnancy, and Preeclampsia: The Roles of Semen Microbes and the Father.

Authors:  Louise C Kenny; Douglas B Kell
Journal:  Front Med (Lausanne)       Date:  2018-01-04

Review 5.  Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli.

Authors:  George G Zhanel; Michael A Zhanel; James A Karlowsky
Journal:  Can J Infect Dis Med Microbiol       Date:  2018-01-30       Impact factor: 2.471

Review 6.  Pharmacological Interventions for Bacterial Prostatitis.

Authors:  Situ Xiong; Xiaoqiang Liu; Wen Deng; Zhengtao Zhou; Yulei Li; Yechao Tu; Luyao Chen; Gongxian Wang; Bin Fu
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

7.  Frequency and clinical significance of prostatic involvement in men with febrile urinary tract infection: a prospective observational study.

Authors:  Thayyil Shahilal Arjunlal; Surendran Deepanjali; Ramanitharan Manikandan; Rajappa Medha
Journal:  F1000Res       Date:  2020-06-16

8.  [Acute prostatitis associated with noncancerous prostate at the Lubumbashi University Clinics: epidemioclinical and therapeutic features].

Authors:  Manix Ilunga Banza; Trésor Kibangula Kasanga; Augustin Kibonge Mukakala; Yannick Tietie Ben N'dwala; Christelle Ngoie Ngoie; Vincent De Paul Kaoma Cabala; Néron Tapenge Shutsha; Lire Ipani Lire; Eric Wakunga Unen; Nathalie Dinganga Kapessa
Journal:  Pan Afr Med J       Date:  2020-12-01

Review 9.  Oral Fosfomycin Formulation in Bacterial Prostatitis: New Role for an Old Molecule-Brief Literature Review and Clinical Considerations.

Authors:  Andrea Marino; Stefano Stracquadanio; Carlo Maria Bellanca; Egle Augello; Manuela Ceccarelli; Giuseppina Cantarella; Renato Bernardini; Giuseppe Nunnari; Bruno Cacopardo
Journal:  Infect Dis Rep       Date:  2022-08-18

10.  Escherichia coli Nissle 1917 as adjuvant therapy in patients with chronic bacterial prostatitis: a non-blinded, randomized, controlled trial.

Authors:  Celeste Manfredi; Francesco P Calace; Ferdinando Fusco; Carmelo Quattrone; Dario Giordano; Felice Crocetto; Massimiliano Creta; Marco De Sio; Davide Arcaniolo
Journal:  World J Urol       Date:  2021-07-02       Impact factor: 4.226

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.